Law360, New York (August 10, 2010, 5:11 PM ET) -- The U.S. Securities and Exchange Commission has launched a formal probe into SciClone Pharmaceuticals Inc., and the U.S. Department of Justice has asked for a meeting with the company regarding its compliance with the Foreign Corrupt Practices Act.
SciClone said in a quarterly report filed with the SEC on Monday that it has received a subpoena from the SEC and a letter from the DOJ, both of which relate to investigations concerning SciClone's sale, licensing and marketing of its products in foreign countries, including China....
Feds Eyeing SciClone For Possible FCPA Violations
To view the full article, take a free trial now.
